← Back to news

Markets

Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

Y

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Y

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Y

Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value

Y

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Y

Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development

Y

Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?

Y

Is High Tide Inc. (HITI) Stock Turning Into a Cannabis Growth Story After Record Quarterly Results?

Y

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock

Y

Meet the ETF That Beat the S&P 500 for Over 20 Years -- and History Suggests It's Ready to Pop Again

Y

Why Split With Waymo In Phoenix Could 'Weigh On' Uber Stock

Y

Drinks companies hit out at Germany’s sugar tax plans

Y

Disney $50M antitrust settlement: how to file a claim

Y

EchoStar prepares Dish DBS bankruptcy filing

Y

Maintenance staffing remains multifamily’s biggest labor challenge

Y

Teledyne Technologies (TDY) Reported Robust Organic Growth in Q1

Y

Why The Secret CFO calls this finance leader ‘the most AI-pilled CFO’

Y

Cooke nets Mowi salmon farms in Canada

Y

Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?

Y

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

Y

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Y

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

Y

3 Dividend Stocks Worth Buying More of While the Market Is Distracted

Y

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

Y

Microsoft Heads for Biggest Monthly Loss Since Dot-Com Burst

Y

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

Y

Comcast's NBCU split makes Wall Street's math easier

Y

Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?

Y

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Y

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Y

Warren Buffett Says This ETF Is Perfect for Everyday Investors

Y

Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?

Y

Is Caris Life Sciences, Inc. (CAI) Stock Positioned for Growth With AI-Driven Precision Medicine Expansion?

Y

Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

Y

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

Y

Despite Dropping 26% This Year, Microsoft is a No-Brainer Buy

Y

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Y

Inflation in Eurozone’s Biggest Economies Cools More Than Expected

Y

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Y

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Y

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential

Y

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

Y

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

Y

3 stocks you’ll wish you bought on SpaceX’s nightmare 2-week crash — 1 has 257% upside according to analysts

Y

Joby, Toyota announce joint venture for air taxi production

Y

Grantham Warns Of Biggest Bubble In History, Again

S

OpenAI Could Delay Its IPO Until 2027. What That Means for Microsoft Stock.

Y

Dear Palo Alto Networks Shareholders - Next Stop $400 Per Share

Y

Think you can outsmart the market by letting AI pick stocks? A new study says don’t bother — you can’t beat buy-and-hold

Y

Saia REV: Rapid, Expanded and Visible

Y